Now, a groundbreaking study from the University of California, Berkeley has identified a molecular switch that may help ...

Global biotechnology company NodThera is developing a new class of potent and selective small-molecule NLRP3 inhibitors for the treatment of diseases driven by chronic inflammation, such as ...

In a recent study published in Science Advances, researchers led by Prof. Li Xinjian from the Institute of Biophysics of the ...

ZyVersa highlights newly published data demonstrating that NLRP3 Inhibition attenuates development of AD pathology and neuroinflammation in a ...

Then, in 2001, researchers in California discovered the genetic explanation for his disease: a mutation in a gene called CIAS1 (since renamed NALP3 and then NLRP3), which was later found to cause the ...

The research team led by Professor Chen Haiyong (middle) discovers a mechanism of C-reactive protein that exacerbates inflammation in diabetic kidney ...

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease and ...

A new study from the University of California, Berkeley has uncovered a molecular “switch” that may help control chronic ...

Researchers across 14 medical centers in China, including Peking University People's Hospital, have found that an ...